Connect with us

Hi, what are you looking for?

Top Stories

Editor's Pick

Pfizer to scale down early-stage rare disease research

STOCK PHOTO Image by Mike Ramírez Mx from Pixabay

US pharma giant Pfizer Inc. said on Thursday it is planning to realign its early-stage research into treatments for rare diseases and oncology, to focus on areas like rare and benign hematology.

Pfizer will also move away from having a rare disease research unit to align important rare disease programs to areas across its research units.

“We are refocusing our approach to early discovery and development research in rare disease and oncology,” a spokesperson said in a statement to Reuters, adding that the company will explore externalization opportunities for “a number of highly innovative, niche programs.”

Pfizer said its oncology research portfolio will become even more focused around breast, prostate and hematological cancer franchises.

Financial newspaper Barron’s first reported the news on Thursday. – Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Editor's Pick

The Board of Investments (BoI) has cleared Sinoma Energy Conservation (Cebu) Waste Heat Recovery Co. Inc. to serve as the operator of a 4.5-megawatt...

Economy

In the wake of Covid-19, people are working harder than ever. While many of us thought productivity may dip when we started working from...

Economy

Few individuals can resist the temptation to try before they buy; therefore, it was only a matter of time until online casinos realized this...

Economy

For more than half a decade, the CBD edibles market has been on the rise. Due to these items’ beneficial formulas, people came to...

Disclaimer: SecretsOfRichDads.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 Secrets Of Richdads. All Rights Reserved.